We are live on ! Find out more
PRAX icon

Praxis Precision Medicines
PRAX

92 hedge funds and large institutions have $792M invested in Praxis Precision Medicines in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 9

124% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 17

15% more funds holding

Funds holding: 80 → 92 (+12)

5% more capital invested

Capital invested by funds: $751M → $792M (+$40.8M)

0.09% more ownership

Funds ownership: 6.29% → 6.38% (+0.09%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
92
Holders Change
+12
Holders Change %
+15%
% of All Funds
1.61%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
21
Increased
38
Reduced
17
Closed
9
Calls
$406K
Puts
–
Net Calls
+$406K
Net Calls Change
+$531K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$11.9M
2
BlackRock
BlackRock
New York
+$11.4M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$6.33M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$5.44M
5
GTC
Ghost Tree Capital
New York
+$4.52M

Top Sellers

1
NHAS
Novo Holdings A/S
Denmark
-$11.9M
2
Blackstone Inc
Blackstone Inc
New York
-$8.33M
3
Citadel Advisors
Citadel Advisors
Florida
-$3.98M
4
MIM
Monashee Investment Management
Massachusetts
-$1.83M
5
Morgan Stanley
Morgan Stanley
New York
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
26
Novo Holdings A/S
Denmark
$4.62M -$11.9M -44,030 -73%
GTC
27
Ghost Tree Capital
New York
$4.62M +$4.52M +16,667 New
Charles Schwab
28
Charles Schwab
California
$4.4M +$2.14M +7,880 +99%
Marshall Wace
29
Marshall Wace
United Kingdom
$3.72M +$226K +832 +7%
Jennison Associates
30
Jennison Associates
New York
$3.61M -$37.7K -139 -1%
MWNA
31
Marshall Wace North America
New York
$3.12M +$517K +1,907 +20%
ECM
32
Endurant Capital Management
California
$2.84M -$831K -3,064 -23%
Two Sigma Investments
33
Two Sigma Investments
New York
$2.34M -$1.04M -3,845 -31%
N
34
Nuveen
North Carolina
$2.32M +$94.4K +348 +4%
RJA
35
Raymond James & Associates
Florida
$2.19M +$35.5K +131 +2%
Millennium Management
36
Millennium Management
New York
$2.07M +$916K +3,377 +83%
Goldman Sachs
37
Goldman Sachs
New York
$2.01M +$407K +1,500 +26%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.92M +$627K +2,311 +50%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
39
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.52M +$1.48M +5,467 New
TCM
40
Tekla Capital Management
Massachusetts
$1.39M – – –
AA
41
ALPS Advisors
Colorado
$1.02M -$43.4K -160 -4%
Swiss National Bank
42
Swiss National Bank
Switzerland
$888K – – –
Citigroup
43
Citigroup
New York
$705K +$22K +81 +3%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$659K +$119K +438 +23%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$654K +$31.2K +115 +5%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$582K – – –
AWA
47
Alta Wealth Advisors
Massachusetts
$574K – – –
Two Sigma Advisers
48
Two Sigma Advisers
New York
$555K +$107K +393 +24%
VFA
49
Values First Advisors
Tennessee
$490K +$479K +1,765 New
Bank of America
50
Bank of America
North Carolina
$462K +$195K +717 +75%
1
2
3 4 5

PRAX Hedge Fund Activity: Q3 2021 in Review

92 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2021, worth a combined $792M — up 5.4% from $751M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new PRAX positions and 9 closed out — a net gain of 12 holders — while 38 added to existing stakes and 17 trimmed.

The largest buyer was Vanguard Group, adding an estimated $11.9M. The largest seller was Novo Holdings A/S, cutting an estimated $11.9M.

  • 92 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2021, up from 80 in Q2 2021.
  • Funds reported $792M of Praxis Precision Medicines stock for Q3 2021, up 5.4% quarter-over-quarter.
  • 21 funds opened new Praxis Precision Medicines positions in Q3 2021 and 9 closed out, a net change of +12 holders.
  • The largest Praxis Precision Medicines buyer in Q3 2021 was Vanguard Group, an estimated $11.9M added.
  • The largest Praxis Precision Medicines seller in Q3 2021 was Novo Holdings A/S, an estimated $11.9M sold.

Based on aggregated 13F filings for Q3 2021.